04.09.13
GE Healthcare has signed a contract with iBio, Inc. to design a new multipurpose manufacturing plant for Bio-Manguinhos/Fiocruz in Brazil. The alliance combines iBio's plant-based manufacturing platform, iBioLaunch, with GE’s capabilities in process design and start-to-finish biopharma and vaccine manufacturing technologies.
Bio-Manguinhos/Fiocruz is a manufacturer of immunobiologicals for public health needs to support Brazilian Ministry of Health programs. It has invested in the development of bioprocess technologies such as iBioLaunch, through a co-development agreement with iBio and its R&D collaborator Fraunhofer USA Center for Molecular Biotechnology (FCMB).
Olivier Loeillot, general manager of Enterprise Solutions at GE Healthcare, said, "Vaccines are vital in the fight against global disease and we're pleased to be working with Bio-Manguinhos/Fiocruz on this important project. GE Healthcare's global capabilities and industry-leading expertise in biopharmaceutical manufacturing technologies, coupled with iBio's innovative technology and experience in plant-based protein expression, provide a solid foundation for this design project. By working closely with the team at Bio-Manguinhos/Fiocruz we will together design a state-of-the-art, technologically-advanced facility that's ready to meet the vaccine needs of tomorrow."
Artur Couto, director of Bio-Manguinhos/Fiocruz, said, "In order to accomplish our mission and to meet the Brazilian Ministry of Health's demands, we are constantly investing in innovative technologies. The agreement with GE Healthcare is important because it will allow us to build a new facility based on a very innovative platform and address an important need of the Brazilian Ministry of Health."
Bio-Manguinhos/Fiocruz is a manufacturer of immunobiologicals for public health needs to support Brazilian Ministry of Health programs. It has invested in the development of bioprocess technologies such as iBioLaunch, through a co-development agreement with iBio and its R&D collaborator Fraunhofer USA Center for Molecular Biotechnology (FCMB).
Olivier Loeillot, general manager of Enterprise Solutions at GE Healthcare, said, "Vaccines are vital in the fight against global disease and we're pleased to be working with Bio-Manguinhos/Fiocruz on this important project. GE Healthcare's global capabilities and industry-leading expertise in biopharmaceutical manufacturing technologies, coupled with iBio's innovative technology and experience in plant-based protein expression, provide a solid foundation for this design project. By working closely with the team at Bio-Manguinhos/Fiocruz we will together design a state-of-the-art, technologically-advanced facility that's ready to meet the vaccine needs of tomorrow."
Artur Couto, director of Bio-Manguinhos/Fiocruz, said, "In order to accomplish our mission and to meet the Brazilian Ministry of Health's demands, we are constantly investing in innovative technologies. The agreement with GE Healthcare is important because it will allow us to build a new facility based on a very innovative platform and address an important need of the Brazilian Ministry of Health."